Consonance Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Consonance Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-6,218,903	Closed	-$91.9M	–	27
2017 Q1	$91.9M	Buy	6,218,903 +425,000	+7%	+$6.88M	9.63%	1
2016 Q4	$93.7M	Buy	5,793,903 +2,095,000	+57%	+$38M	10.3%	2
2016 Q3	$67.1M	Buy	+3,698,903	New	+$72.3M	6.45%	7
2013 Q4	–	Sell	-105,000	Closed	-$352K	–	29
2013 Q3	$352K	Buy	+105,000	New	+$277K	0.09%	25

Other funds holding HZNP

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Consonance Capital Management's HZNP Position: Q2 2017 in Review

Consonance Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2017, closing a stake of 6,218,903 shares — an estimated $91.9M sold.

Consonance Capital Management first reported a position in HZNP in Q3 2013 and held it in 4 quarters. The position peaked at $93.7M in Q4 2016. 190 funds tracked by Wall St. Rank hold HZNP as of Q2 2017.

Consonance Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2017 after selling out during the quarter.
Consonance Capital Management sold 6,218,903 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2017, an estimated $91.9M.
Consonance Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 4 quarters.
Consonance Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $93.7M in Q4 2016.
190 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2017.

Based on Consonance Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.